List view / Grid view
Phase I study shows that mRNA-based individualised neoantigen specific immunotherapy…
Phase I study shows that mRNA-based individualised neoantigen specific immunotherapy (iNeST) vaccines can be used to stimulate T cells to recognise neoantigens in pancreatic cancer patients.
BioNTech expands clinical oncology portfolio with first patient dosed in…
BioNTech expands clinical oncology portfolio with first patient dosed in Phase II trial of mRNA-based vaccine for colorectal cancer.
BioNTech is evaluating its investigational therapeutic mRNA-based cancer vaccine, BNT111,…
BioNTech is evaluating its investigational therapeutic mRNA-based cancer vaccine, BNT111, in combination with Libtayo® (cemiplimab) for the treatment of melanoma.
Pfizer and BioNTech's data on BNT162b2, their COVID-19 vaccine, has…
Pfizer and BioNTech's data on BNT162b2, their COVID-19 vaccine, has been published in a new scientific paper, demonstrating its 95 percent efficacy rate.
